Skip navigation

Please use this identifier to cite or link to this item: http://10.10.120.238:8080/xmlui/handle/123456789/854
Full metadata record
DC FieldValueLanguage
dc.rights.licenseAll Open Access, Gold, Green-
dc.contributor.authorSreeharsha N.en_US
dc.contributor.authorRajpoot K.en_US
dc.contributor.authorTekade M.en_US
dc.contributor.authorKalyane D.en_US
dc.contributor.authorNair A.B.en_US
dc.contributor.authorVenugopala K.N.en_US
dc.contributor.authorTekade R.K.en_US
dc.date.accessioned2023-11-30T08:52:15Z-
dc.date.available2023-11-30T08:52:15Z-
dc.date.issued2020-
dc.identifier.issn1999-4923-
dc.identifier.otherEID(2-s2.0-85091573596)-
dc.identifier.urihttps://dx.doi.org/10.3390/pharmaceutics12100920-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/854-
dc.description.abstractThe aim of this study was to design, optimize, and develop metronidazole (Met) loaded nanoparticles (MetNp) by employing quality-based design (QbD) as well as a risk assessment methodology. A fractional factorial design was used by selecting five independent variables viz., chitosan concentration, tripolyphosphate concentration, and acetic acid concentration as material attributes, stirring speed, and stirring time as process parameters, whereby their influence on two dependent variables such as particle size (PS) and %entrapment efficiency (%EE) was studied. MetNp were synthesized by employing an ionic-gelation technique and optimized formula obtained from the QbD design study. PS and %EE studies revealed the formation of MetNp with 558.06 ± 2.52 nm and 59.07 ± 2.15%, respectively. Furthermore, a Met release study in various simulated gastro-intestinal media suggested pH-triggered (pH > 7.0) and sustained release profile of Met from Eudragit S100 enteric-coated MetNp capsule (MetNp cap). Moreover, the stability investigation of formulations confirmed good stability with respect to their PS and residual drug content (RDC) at different temperature conditions. In conclusion, the QbD method was effectively utilized in the development of MetNp and enteric-coated MetNp cap depicting their potential to release Met through MetNp cap only in the colon region and can be utilized for the treatment of amoebiasis in the colon. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.sourcePharmaceuticsen_US
dc.subjectChitosanen_US
dc.subjectColon-specific deliveryen_US
dc.subjectEudragit S100en_US
dc.subjectMetronidazoleen_US
dc.subjectNanoparticlesen_US
dc.subjectQbDen_US
dc.titleDevelopment of metronidazole loaded chitosan nanoparticles using QBD approach—a novel and potential antibacterial formulationen_US
dc.typeJournal Articleen_US
Appears in Collections:Journal Article

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.